0001213900-17-010406.txt : 20171010 0001213900-17-010406.hdr.sgml : 20171010 20171010085932 ACCESSION NUMBER: 0001213900-17-010406 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20171010 DATE AS OF CHANGE: 20171010 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Roka BioScience, Inc. CENTRAL INDEX KEY: 0001472343 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 270881542 STATE OF INCORPORATION: DE FISCAL YEAR END: 1216 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-88250 FILM NUMBER: 171128870 BUSINESS ADDRESS: STREET 1: 20 INDEPENDENCE BOULEVARD CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 908-605-4700 MAIL ADDRESS: STREET 1: 20 INDEPENDENCE BOULEVARD CITY: WARREN STATE: NJ ZIP: 07059 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Painter Edward H CENTRAL INDEX KEY: 0001718882 FILING VALUES: FORM TYPE: SC 13D MAIL ADDRESS: STREET 1: 544 KING STREET CITY: CHAPPAQUA STATE: NY ZIP: 10514 SC 13D 1 sc13d1017painter_rokabio.htm SCHEDULE 13D

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934 (Amendment No. __)

 

Roka Bioscience, Inc
(Name of Issuer)

 

Common Shares
(Title of Class of Securities)

 

775431109
(CUSIP Number)

 

Edward Painter, 544 King St Chappaqua NY 10514, 914 841 8818
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
 
September 29, 2017
(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other parties to whom copies are to be sent.

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

  

 

 

Page 2

SCHEDULE 13D

 

CUSIP No.  641119 102

 

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Edward Painter
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)  ☐ 

(b)  ☐

3 SEC USE ONLY
 
4 SOURCE OF FUNDS (See Instructions)
Personal Funds
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)          ☐
                     
6 CITIZENSHIP OR PLACE OF ORGANIZATION
USA

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH		 7 SOLE VOTING POWER
340,000
8 SHARED VOTING POWER
 
9 SOLE DISPOSITIVE POWER
340,000
10 SHARED DISPOSITIVE POWER
 

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
340,000
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)     ☐
    
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.79%
14 TYPE OF REPORTING PERSON (See Instructions)
Individual

 

 

 

Page 3

 

Item 1.Security and Issuer

 

Item 2.Identity and Background

 

(a)Edward Painter

 

(b)544 King St, Chappaqua NY 10514

 

(c)Founder & CEO A2A Pharmaceuticals

 

(d)None

 

(e)None

 

(f)USA

 

Item 3.Source and Amount of Funds or Other Considerations

 

Personal funds

 

Item 4.Purpose of Transaction

 

Edward Painter purchased shares with the intention of seeking a business combination with A2A Pharmaceuticals, a private biotechnology company. He may sell shares or buy additional shares or change his purpose of transacting in the future.

 

Item 5.Interest in Securities of the Issuer

 

(a)340,000 shares (6.79%)

 

(b)340,000 sole power to vote and dispose of

 

Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

None

 

Item 7.Material to Be Filed as Exhibits

 

None

 

 

 

Page 4

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

October 9, 2017  
Dated  
   
/s/ Edward Painter  
Signature  
   
Edward Painter  
Name/Title  

 

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

 

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).